跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AMIKACIN SULFATE INJECTION USP - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AMIKACIN SULFATE INJECTION USP
Authorized
STANDARD
AMIKACIN SULFATE INJECTION USP
marcan pharmaceuticals inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f2c20f36151555e2
Company
marcan pharmaceuticals inc
Type
Standard
Approval Details
Approval Id
f2c20f36151555e2
Drug Approval Canada Name
AMIKACIN SULFATE INJECTION USP
Product Name
AMIKACIN SULFATE INJECTION USP
Status
Marketed
Status Date
2019-03-01
Original Market Date
2019-03-01
Din
02481073
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular , Intravenous
Schedule
Prescription
Ahfs
08:12.02
Atc Original
J01GB06 AMIKACIN
Atc Name
j 01 gb 06
Aig Number
0111922001
Company Name
marcan pharmaceuticals inc
Company Address
2 Gurdwara Rd., Suite 112, Ottawa, Ontario, Canada, K2E 1A2
Active Ingredients
AMIKACIN (AMIKACIN SULFATE)
500 MG / 2 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f2c20f36151555e2
Type
Standard
Back to Health Canada Approvals